VP of Product - Hereditary Cancer Testing

The Vice President of Product, Hereditary Cancer Testing (HCT), is a visionary executive responsible for the strategic direction, development, and commercial success of the company’s germline genetic testing portfolio. This role oversees the entire product lifecycle—from clinical validation and R&D coordination to large-scale commercial launch and P&L management.  

You will lead the innovation of hereditary screening tools (e.g., Breast/Ovarian, Lynch Syndrome, and Multi-Cancer Panels), ensuring they deliver medically actionable insights that empower patients and clinicians to manage cancer risk proactively. The ideal candidate is an entrepreneurial leader with a proven track record in product management for Hereditary Genetics and a deep understanding of how to bridge technical NGS development with high-impact commercial execution.  

Responsibilities:

• Strategic HCT Portfolio Roadmap: Develop and execute a comprehensive roadmap for hereditary cancer screening, focusing on high-penetrance genes, expanded panels. eQTLs and polygenic risk scores (PRS). Prioritize product features that enhance clinical utility, such as improved VUS (Variant of Uncertain Significance) resolution and family-member testing programs.  

• Market & Competitive Analysis: Lead competitive intelligence against industry leaders (e.g., Myriad Genetics, Invitae and Natera) to identify gaps in turn-around time (TAT), price, and report clarity. Collaborate with Market Access to ensure product designs meet the criteria for reimbursement from CMS and private payers. 

• Product Lifecycle Management: Oversee upstream Product Managers in end-to-end lifecycle management for HCT services, ensuring successful launches and continuous enhancements of assays and platforms. Oversee the development of digital clinician portals and patient-facing results interfaces to streamline the genetic counseling workflow. Partner with R&D, Medical Affairs, and Laboratory Operations to implement a rigorous Phase-Gated Product Development Process (PDP). 

• Commercial Strategy Execution: Drive product positioning, messaging, and go-to-market (GTM) strategies by guiding downstream Marketing Managers and collaborating closely with sales, market access, and medical affairs teams to maximize adoption and clinical impact. Guide the development of sales training, physician marketing, and patient-advocacy engagement. 

• Portfolio P&L Management: Maintain full accountability for the HCT product portfolio P&L, focusing on revenue growth, resource allocation, and measurable business outcomes. 

• Stakeholder Engagement: Build strong relationships with key opinion leaders, oncologists, genetic counselors, and patient advocacy groups to inform product strategy and support clinical adoption.  

• Regulatory & Compliance Leadership: Ensure product development and commercialization meet regulatory requirements, including FDA, CLIA, CAP, and international standards.

Required Skills:

• Strategic Market Access & Value Storytelling: Ability to develop and communicate a compelling value proposition that demonstrates the clinical and economic benefits of HCT to payers, providers, and health systems. 

• Patient-Centric Advocacy & Empathy: Specialized capability to integrate the patient journey and voice into product design and commercial strategy, including engagement with patient advocacy groups to address barriers such as access, education, cost, and equity. 

• Cross-Functional Matrix Leadership: Ability to influence and lead multidisciplinary teams—including R&D, Medical Affairs, Regulatory, and Sales—without direct authority, harmonizing these groups to ensure products remain clinically relevant and commercially successful. 

• Agile & Adaptive Decision-Making: High-level ability to make critical, data-informed decisions under pressure in the rapidly evolving diagnostics landscape, including strategic agility to pivot the product roadmap in response to new clinical discoveries or regulatory changes. 

• Regulatory & Quality Expertise: Mastery of CLIA/CAP and NYSDOH requirements; experience with FDA 510(k) or PMA submissions for IVD products is highly preferred.

Required Education & Experience:

• Required Education: Bachelor’s degree in Life Sciences required; MBA, MS in Genetic Counseling, or PhD strongly preferred. 

• Preferred Education: Advanced degree such as an MBA, or PhD is highly preferred, bridging the gap between complex science, clinical reporting, and business strategy. 

• Specialized Knowledge: Deep understanding of inherited cancers, cancer genomics, clinical workflows, and the evolving landscape of hereditary cancer testing. Deep understanding of Next-Generation Sequencing (NGS) workflows, including targeted enrichment, bioinformatics pipelines, and variant classification. 

• Commercial Knowledge: Extensive knowledge of market demands, technology trends, and the regulatory environment for hereditary cancer. Proven ability to manage a multi-million dollar product line, including budgeting, forecasting, and gross margin optimization.

Preferred Experience:

• Leadership Tenure: Minimum of 10+ years in the molecular diagnostics or genomics industry, with at least 5 years in a senior leadership role. 

• Portfolio Growth: Documented success in launching at least 2-3 major hereditary cancer products from concept through commercial scale.

This role works with Personal Health Information (PHI) on a regular basis both in paper and electronic form, and therefore training relating to HIPAA/PHI privacy, General Policies and Procedure Compliance training and security training will be required upon hire.